Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Recursion Pharmaceuticals Inc RXRX

Healthcare Biotechnology
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous... see more

Current News (NDAQ:RXRX)

Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks

GlobeNewswire 2 days ago

Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025

GlobeNewswire 9 days ago

Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire November 5, 2025

Recursion Announces CEO Transition Plan to Drive Next Phase of Growth

GlobeNewswire November 5, 2025

Recursion to Participate in Upcoming Investor Conferences

GlobeNewswire November 4, 2025

Recursion to Report Third Quarter 2025 Business Updates and Financial Results on November 5th

GlobeNewswire October 28, 2025

Recursion to Participate in Upcoming Investor Conferences

GlobeNewswire August 27, 2025

Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire August 5, 2025

Recursion to Report Second Quarter 2025 Business Updates and Financial Results on August 5th

GlobeNewswire July 29, 2025
View More News ››

Opinion & Analysis (NDAQ:RXRX)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:RXRX)

Sell buddy sell.

Otherwise you guys will be going down big-time with this stock today
coolfooldumbguy - November 4, 2025

Buy buddy buy.

Otherwise FOMO
coolfooldumbguy - October 15, 2025

Using technical analysis for this stock.

It is signalling a continuing uptrend for shareholders today so good luck to all of you
coolfooldumbguy - July 21, 2025

Buy buddy buy.

Otherwise
coolfooldumbguy - June 20, 2025

MIT & RXRX RELEASE NEXT GEN AI MODEL CALLED BOLTZ-2

MIT and Recursion Release Boltz-2: Next Generation AI Model to Predict Binding Affinity at Unprecedented Speed, Scale, and Accuracy...
Humanist - June 6, 2025

Still holding this stock.

This stock is signalling a continuing uptrend for shareholders today anyway
coolfooldumbguy - June 5, 2025
View more Bullboard ››

Cielo Waste Solutions Corp.

Cielo Waste Solutions Corp.

Cielo Waste Solutions Corp. operates as a waste to fuels company, focuses on wood waste byproducts conversion to renewable ...
View More »